

DAFTAR PUSTAKA

1. V'kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus biology and replication: implications for SARS-CoV-2. *Nat Rev Microbiol.* 2021;19(3):155–70.
2. Rozaliyani A, Savitri AI, Setianingrum F, Shelly TN, Ratnasari V, Kuswindarti R, et al. Factors Associated with Death in COVID-19 Patients in Jakarta, Indonesia: An Epidemiological Study. *Acta Med Indones.* 2020;52(3):246–54.
3. Del Sole F, Farcomeni A, Loffredo L, Carnevale R, Menichelli D, Vicario T, et al. Features of severe COVID-19: A systematic review and meta-analysis. *Eur J Clin Invest.* 2020;50(10):1–7.
4. Karyono DR, Wicaksana AL. Current prevalence, characteristics, and comorbidities of patients with COVID-19 in Indonesia. *J Community Empower Heal.* 2020;3(2):77.
5. Joseph T MM. International pulmonologist's consensus on COVID-19. International pulmonologist's consensus group on COVID-19. 2020.
6. Azwar MK, Setiati S, Rizka A, Fitriana I, Saldi SRF, Safitri ED. Clinical Profile of Elderly Patients with COVID-19 hospitalised in Indonesia's National General Hospital. *Acta Med Indones.* 2020;52(3):199–205.
7. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet.* 2020;395(10229):1054–62.
8. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China. *J Am Med Assoc.* 2020;323(13):1239.
9. Diaz J, Appiah J, Askie L, Baller A, Banerjee A, Barkley S, Bertagnolio S, et al. COVID-19: Clinical management Living guidance. World Health Organization. 2021.
10. Parasher A. COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. *Postgrad Med J.* 2021;97(1147):312–20.
11. WHO Team. COVID-19 vaccine tracker and landscape [Internet]. World Health Organization. 2021 [cited 2021 Jul 30].

12. Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE, et al. COVID-19 and comorbidities: Deleterious impact on infected patients. *J Infect Public Health*. 2020;13(12):1833–9.
13. Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its Impact on Patients with COVID-19. *SN Compr Clin Med*. 2020 Aug;2(8):1069–76.
14. World Health Organization. Coronavirus [Internet]. Geneva: WHO. 2020 [cited 2021 Jul 30].
15. Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. *Nat Microbiol*. 2020;5(4):536–44.
16. Denis M, Vandeweerd V, Verbeeke R, Laudisoit A, Reid T, Hobbs E, et al. Covipendium: Information available to support the development of medical countermeasures and interventions against COVID-19. *Transdiscipl Insights*. 2021;4(1):1–296.
17. Kirtipal N, Bharadwaj S, Kang SG. From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses. *Infect Genet Evol*. 2020;85:104502.
18. Salian VS, Wright JA, Vedell PT, Nair S, Li C, Kandimalla M, et al. COVID-19 Transmission, Current Treatment, and Future Therapeutic Strategies. *Mol Pharm*. 2021;18(3):754–71.
19. Health WHO, Programme E, Panel EA, Preparedness IPC, Guidance IPC, Group D, et al. Transmission of SARS-CoV-2: implications for infection prevention precautions. 2020;(6):1–10.
20. Mousavizadeh L, Ghasemi S. Genotype and phenotype of COVID-19: Their roles in pathogenesis. *J Microbiol Immunol Infect*. 2020; 54(2):159-63.
21. Shibata S, Arima H, Asayama K, Hoshide S, Ichihara A, Ishimitsu T, et al. Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19. *Hypertens Res*. 2020;43(10):1028–46.
22. Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for Gastrointestinal Infection of SARS-CoV-2. *Gastroenterology*. 2020;158(6):1831-1833.e3.

23. Meng X, Deng Y, Dai Z, Meng Z. COVID-19 and anosmia: A review based on up-to-date knowledge Xiangming. *Am J Otolaryngol*. 2020; 41(5):102581.
24. Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, eds. *Harrison's Principles of Internal Medicine*. 19th ed. McGraw Hill; 2015.
25. Pathangey G, Fadadu PP, Hospodar AR, Abbas AE. Angiotensin-converting enzyme 2 and COVID-19: Patients, comorbidities, and therapies. *Am J Physiol - Lung Cell Mol Physiol*. 2021;320(3):L301–30.
26. Tosepu R, Gunawan J, Effendy DS, Ahmad LOAI, Lestari H, Bahar H, et al. Correlation between weather and Covid-19 pandemic in Jakarta, Indonesia. *Sci Total Environ*. 2020;725:138436.
27. Satuan Tugas Penanganan COVID-19. Peta Sebaran | Covid19.go.id [Internet]. 2021. [cited 2021 Aug 6].
28. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *J Am Med Assoc*. 2020;323(11):1061–9.
29. Taneja S, Mehtani R, Chawla YK. Gastrointestinal and Liver Manifestations of COVID-19. Vol. 56, *Ann Natl Acad Med Sci*. 2020. p. 091–8.
30. Pakhchanian H, Raiker R, Mukherjee A, Khan A, Singh S, Chatterjee A. Outcomes of COVID-19 in CKD Patients: A Multicenter Electronic Medical Record Cohort Study. *Clin J Am Soc Nephrol*. 2021;16(5):785–6.
31. Gagliardi I, Patella G, Michael A, Serra R, Provenzano M, Andreucci M. COVID-19 and the Kidney: From Epidemiology to Clinical Practice. *J Clin Med*. 2020;9(8):2506.
32. Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. COVID-19 and Cardiovascular Disease. *Circulation*. 2020;141:1648–55.
33. Gazzaz ZJ. Diabetes and COVID-19. *Open Life Sci*. 2021;297–302.
34. Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. *Nat Rev Endocrinol*. 2021;17(1):11–30.

35. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost.* 2020;18(4):844–7.
36. Zhu J, Zhong Z, Ji P, Li H, Li B, Pang J, et al. Clinicopathological characteristics of 8697 patients with COVID-19 in China: A meta-analysis. *Fam Med Community Heal.* 2020;8(2):1–11.
37. Gupta N, Ish P, Kumar R, Dev N, Yadav SR, Malhotra N, et al. Evaluation of the clinical profile, laboratory parameters and outcome of two hundred COVID-19 patients from a tertiary centre in India. *Monaldi Arch Chest Dis.* 2020;90(4):675–82.
38. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The lancet.* 2020 Feb 15;395(10223):497-506.
39. Funk CD, Ardakani A. A Novel Strategy to Mitigate the Hyperinflammatory Response to COVID-19 by Targeting Leukotrienes. *Front Pharmacol.* 2020;11.
40. National Center for Immunization and Respiratory Diseases (U.S.) Division of Viral Diseases. Certain Medical Conditions and Risk for Severe COVID-19 Illness | CDC [Internet]. Centers for Disease Control and Prevention. 2020 [cited 2021 Aug 5].
41. Hamid S, Mir MY, Rohela GK. Novel coronavirus disease (COVID-19): a pandemic (epidemiology, pathogenesis and potential therapeutics). *New Microbes New Infect.* 2020;35:100679.
42. Leung JM, Yang CX, Tam A, Shaipanich T, Hackett TL, Singhera GK, et al. ACE-2 expression in the small airway epithelia of smokers and COPD patients: Implications for COVID-19. *Eur Respir J.* 2020;55(5).
43. Valderas JM, Starfi B, Sibbald B. Defining Comorbidity: Implications for Understanding Health and Health Services. *Ann Fam Med.* 2009;7(4):357–63.
44. Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. *Eur Respir J.* 2020;55(5):14.
45. Ramatillah DL, Isnaini S. Treatment profiles and clinical outcomes of COVID-19 patients at private hospital in Jakarta. *PLoS One.* 2021;16:1–11.

46. Sudoyo A, Setiati S, Alwi I, Simadibrata K M, Hadi S, Syam A. Buku Ajar Ilmu Penyakit Dalam Jilid II. 6th ed. Jakarta: Internal Publishing; 2009.
47. Patel VB, Clarke N, Wang Z, Fan D, Parajuli N, Basu R, et al. Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: A positive feedback mechanism in the RAS. *J Mol Cell Cardiol.* 2014;66:167–76.
48. Haga S, Yamamoto N, Nakai-Murakami C, Osawa Y, Tokunaga K, Sata T, et al. Modulation of TNF-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-production and facilitates viral entry. *Proc Natl Acad Sci.* 2008;105(22):7809–14.
49. Fernandez C, Rysä J, Almgren P, Nilsson J, Engström G, Orho-Melander M, et al. Plasma levels of the proprotein convertase furin and incidence of diabetes and mortality. *J Intern Med.* 2018;284(4):377–87.
50. Liu F, Long X, Zhang B, Zhang W, Chen X, Zhang Z. ACE2 expression in pancreas may cause pancreatic damage after SARS-CoV-2 infection. *Clin Gastroenterol Hepatol.* 2020 Aug 1;18(9):2128-30.
51. Feng Z, Diao B, Wang R, Wang G, Wang C, Tan Y, et al. The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Directly Decimates Human Spleens and Lymph Nodes. *MedRxiv.* 2020;2:1–18.
52. Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. *Cardiovasc Res.* 2020;116(6):1097–100.
53. Sama IE, Ravera A, Santema BT, Van Goor H, Ter Maaten JM, Cleland JGF, et al. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. *Eur Heart J.* 2020;41(19):1810–7.
54. Higham A, Mathioudakis A, Vestbo J, Singh D. COVID-19 and copd: A narrative review of the basic science and clinical outcomes. *Eur Respir Rev.* 2020;29(158):1–13.
55. Kompaniyets L, Goodman AB, Belay B, Freedman DS, Sucusky MS, Lange SJ, et al. Body Mass Index and Risk for COVID-19–Related Hospitalization, Intensive Care Unit Admission, Invasive Mechanical Ventilation, and Death — United States, March–December 2020. *MMWR Surveill Summ.* 2021;70(10):355–61.

56. Zhou Y, Chi J, Lv W, Wang Y. Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19). *Diabetes Metab Res Rev*. 2021;37(2).
57. Jennifer, R., Green, W. D., Alwarawrah, Y., Nichols, A. G., Eisner, W. D. Obesity-induced changes in T cell metabolism are associated with impaired memory T cell response to influenza and are not reversed with weight loss. *J Infect Dis*. 2018;219(10):1652–62.
58. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. *Kidney Int*. 2020;97(5):829–38.
59. Puelles VG, Lütgehetmann M, Lindenmeyer MT, Sperhake JP, Wong MN, Allweiss L, Chilla S, Heinemann A, Wanner N, Liu S BF. Multiorgan and Renal Tropism of SARS-CoV-2. *N Engl J Med*. 2020;383(6):590–2.
60. Deng G, Yin M, Chen X, Zeng F. Clinical determinants for fatality of 44,672 patients with COVID-19. *Crit Care*. 2020;24(1):1–3.
61. Yang H, Lu S. COVID-19 and tuberculosis. *J Transl Intern Med*. 2020;8(2):59–65.
62. Lisco G, De Tullio A, Jirillo E, Giagulli VA, De Pergola G, Guastamacchia E, Triggiani V. Thyroid and COVID-19: a review on pathophysiological, clinical and organizational aspects. *J Endocrinol Invest*. 2021;44(9):1801-14.
63. Topless R, Gaffo A, Stamp L, Robinson PC, Dalbeth N, Merriman T. Gout and Coronavirus Disease-19 (COVID-19): The Risk of Diagnosis and Death in the UK Biobank. *SSRN Electron J*. 2021;19:1–27.
64. Zhang XM, Jiao J, Cao J, Huo XP, Zhu C, Wu XJ, et al. Frailty as a predictor of mortality among patients with COVID-19: a systematic review and meta-analysis. *BMC Geriatr*. 2021;21(1):1–11.
65. Caliendo A, Hanson K. COVID-19: Diagnosis - UpToDate [Internet]. UpToDate. 2021 [cited 2021 Dec 4].
66. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Eurosurveillance*. 2020;25(3):1–8.
67. Bustin SA. RT-qPCR Testing of SARS-CoV-2: A Primer. 2020; 21(8): 3004.

68. Scohy A, Anantharajah A, Bodéus M, Kabamba-Mukadi B, Verroken A, Rodriguez-Villalobos H. Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis. *J Clin Virol.* 2020;129.
69. Sutaryono S, Andasari SD, Kasjono HS. Diagnosis and epidemiology of Coronavirus (COVID-19) outbreak in Indonesia. *J Teknol Lab.* 2020;9(1):49–57.
70. Li K, Wu J, Wu F, Guo D, Chen L, Fang Z, et al. The Clinical and Chest CT Features Associated with Severe and Critical COVID-19 Pneumonia. *Invest Radiol.* 2020;55(6):327–31.
71. Li X, Li T, Wang H. Treatment and prognosis of COVID-19: Current scenario and prospects (Review). Vol. 20, *Experimental and Therapeutic Medicine.* 2020;21(1):1-10.
72. Fang X, Li S, Yu H, Wang P, Zhang Y, Chen Z, et al. Epidemiological, comorbidity factors with severity and prognosis. *Aging (Albany NY).* 2020;12(13):12493–503.
73. Sastroasmoro S. *Dasar-dasar Metodologi Penelitian Klinis.* 5th ed. Jakarta: Sagung Seto; 2014.
74. Dorland WA. *Kamus Saku Kedokteran Dorland.* 31st ed. Singapore: Elsevier Inc; 2015.
75. Kbbi KB. *Kamus Besar Bahasa Indonesia (KBBI).* Kementerian Pendidikan Dan Budaya. 2016.
76. Surendra H, Elyazar IR, Djaafara BA, Ekawati LL, Saraswati K, Adrian V, et al. Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: A hospital-based retrospective cohort study. *Lancet Reg Heal - West Pacific.* 2021;9:100108.
77. Marik PE, ED S, A Q, D S. Gender-based disparities in COVID-19 patient outcomes.pdf. *Journal of Investigative Medicine;* 2021. p. 814–8.
78. Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ICU admission. *Nat Commun.* 2020;11(1):1–10.
79. Garg S, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, Prill M, Chai SJ, Kirley PD, Alden NB, Kawasaki B. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed

- coronavirus disease 2019—COVID-NET, 14 States, March 1–30, 2020. *Morbidity and mortality weekly report*. 2020;69(15):458.
80. O'Hare AM, Berry K, Fan VS, Crothers K, Eastment MC, Dominitz JA, et al. Age differences in the association of comorbid burden with adverse outcomes in SARS-CoV-2. *BMC Geriatr*. 2021;21(1):1–10.
81. Ruiz-García J, Lerman A, Weisz G, Maehara A, Mintz GS, Fahy M, et al. Age- and gender-related changes in plaque composition in patients with acute coronary syndrome: The PROSPECT study. *EuroIntervention*. 2012;8(8):929–38.
82. Song WJ, Hui CKM, Hull JH, Birring SS, McGarvey L, Mazzone SB, et al. Confronting COVID-19-associated cough and the post-COVID syndrome: role of viral neurotropism, neuroinflammation, and neuroimmune responses. *Lancet Respir Med*. 2021;9(5):533–44.
83. Shoaib N, Noureen N, Munir R, Shah FA, Ishtiaq N, Jamil N, et al. COVID-19 severity: Studying the clinical and demographic risk factors for adverse outcomes. *PLoS One*. 2021;16(8 August):1–10.
84. M. Salazar, J. Barochiner WE el. E. The roles of nausea and vomiting in COVID-19: did we miss something? *Ann Oncol*. 2020;54:2–5.
85. Li J, Huang DQ, Zou B, Yang H, Hui WZ, Rui F, et al. Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. *J Med Virol*. 2021;93(3):1449–58.
86. Kucuk A, Cumhur Cure M, Cure E. Can COVID-19 cause myalgia with a completely different mechanism? A hypothesis. *Clin Rheumatol*. 2020;39(7):2103–4.
87. Chen G, Li X, Gong Z, Xia H, Wang Y, Wang X, et al. Hypertension as a sequela in patients of SARS-CoV-2 infection. *PLoS One*. 2021;16:1–14.
88. Defining Adult Overweight & Obesity | Overweight & Obesity | CDC [Internet]. Centers for Disease Control and Prevention. 2021 [cited 2021 Nov 24].
89. Liu S, Zhi Y, Ying S. COVID-19 and Asthma: Reflection During the Pandemic. *Clin Rev Allergy Immunol*. 2020;59(1):78–88.
90. McQueenie R, Foster HME, Jani BD, Katikireddi SV, Sattar N, Pell JP, et al. Multimorbidity, polypharmacy, and COVID-19 infection within the UK Biobank cohort. *PLoS One*. 2020;15(8 August):1–15.